Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.74
$31.50
$23.62
▼
$35.43
$21.67B0.841.89 million shs2.71 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$494.63
$515.48
$408.75
▼
$609.35
$21.21B0.56667,789 shs1.48 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+78.31%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.99%+3.86%+35.65%+22.84%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%-0.50%-3.60%-8.11%+18.45%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$236.72
$254.83
$186.05
▼
$282.15
$14.77B0.35730,003 shs1.56 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.74
$31.50
$23.62
▼
$35.43
$21.67B0.841.89 million shs2.71 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$494.63
$515.48
$408.75
▼
$609.35
$21.21B0.56667,789 shs1.48 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+78.31%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-10.17%-6.54%+3.82%+19.75%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.99%+3.86%+35.65%+22.84%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%-0.50%-3.60%-8.11%+18.45%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.14
Hold$38.88-5.25% Downside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$310.7531.27% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5013.70% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.85
Moderate Buy$646.0030.60% Upside

Current Analyst Ratings Breakdown

Latest APLS, GMAB, UTHR, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$344.00
9/15/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$287.00
9/14/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$1.11B4.75$0.21 per share196.33$3.24 per share12.66
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.13N/AN/A($2.97) per share-79.70
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.83$1.61 per share21.58$9.10 per share3.82
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B6.67$33.00 per share14.99$164.81 per share3.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%N/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8918.3626.69N/A70.99%32.54%7.71%11/11/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2727.3522.131.8919.08%14.89%7.73%11/5/2026 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$27.9517.7016.682.4841.56%20.18%17.98%11/4/2026 (Estimated)

Latest APLS, GMAB, UTHR, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/5/2026Q2 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.86$7.27+$0.41$7.27$804.65 million$783.30 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.87
3.63
3.16
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
5.73
5.41

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770128.02 million119.70 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.78 million614.17 millionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.89 million39.20 millionOptionable

Recent News About These Companies

United Therapeutics Insider Sold Shares Worth $4,712,580, According to a Recent SEC Filing
September 19 at 9:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-204744621.html
United Therapeutics (NASDAQ:UTHR) EVP Sells $4,129,582.00 in Stock
September 19 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-09-19/
179,235 Shares in United Therapeutics Corporation $UTHR Bought by Bank of America Corp DE
September 19 at 3:22 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-179235-shares-in-united-therapeutics-corporation-uthr-bought-by-bank-of-america-corp-de-2026-09-19/
United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock
September 18 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-evp-sells-8300-shares-of-stock-2026-09-18/
Biotech Options Buzz: UTHR, NMRA, EWTX
September 18 at 11:46 AM  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/options/2026/09/18/biotech-options-buzz-uthr-nmra-ewtx
United Therapeutics (NASDAQ:UTHR) CEO Sells $4,763,205.00 in Stock
September 18 at 6:37 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-uthr-insider-buying-and-selling-2026-09-18/
United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock
September 18 at 4:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31030969
Corient Private Wealth LP Reduces Stake in United Therapeutics Corporation $UTHR
September 18 at 3:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-reduces-stake-in-united-therapeutics-corporation-uthr-2026-09-18/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,763,205.00 in Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-ceo-sells-476320500-in-stock-2026-09-17/
Ameritas Advisory Services LLC Sells 5,124 Shares of United Therapeutics Corporation $UTHR
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ameritas-advisory-services-llc-sells-5124-shares-of-united-therapeutics-corporation-uthr-2026-09-17/
United Therapeutics Insider Sold Shares Worth $4,789,152, According to a Recent SEC Filing
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/united-therapeutics-insider-sold-shares-203756407.html
United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by Analysts
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025914
United Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Recommendation of "Moderate Buy" by Analysts
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-united-therapeutics-corporation-nasdaq-uthr-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-09-16/
Nilda Mesa Sells 228 Shares of United Therapeutics (NASDAQ:UTHR) Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-nilda-mesa-sells-228-shares-of-united-therapeutics-nasdaq-uthr-stock-2026-09-15/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,789,140.00 in Stock
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-united-therapeutics-nasdaq-uthr-ceo-sells-478914000-in-stock-2026-09-15/
Engineers Gate Manager LP Purchases New Stake in United Therapeutics Corporation $UTHR
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-purchases-new-stake-in-united-therapeutics-corporation-uthr-2026-09-15/
United Therapeutics Corporation (UTHR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946245-united-therapeutics-corporation-uthr-presents-at-morgan-stanley-24th-annual-global-healthcare
WINTON GROUP Ltd Trims Holdings in United Therapeutics Corporation $UTHR
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-winton-group-ltd-trims-holdings-in-united-therapeutics-corporation-uthr-2026-09-14/
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,772,325.00 in Stock
September 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31022666
National Pension Service Sells 2,208 Shares of United Therapeutics Corporation $UTHR
September 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-national-pension-service-sells-2208-shares-of-united-therapeutics-corporation-uthr-2026-09-13/
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-united-therapeutics-nasdaq-uthr-ceo-sells-9500-shares-2026-09-11/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$236.72 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$238.46 +1.74 (+0.74%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$34.74 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$34.66 -0.08 (-0.23%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$494.63 0.00 (0.00%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$494.73 +0.10 (+0.02%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas